Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1301 to 1350 of 3761 results for treatment

  1. What are the frequency, timing, severity and predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis?

    predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable)...

  2. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  3. Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup of people with osteoarthritis?

    Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup of people with osteoarthritis? Any...

  4. Bronchiolitis in children (QS122)

    This quality standard covers assessing, diagnosing and managing bronchiolitis in children. It describes high-quality care in priority areas for improvement.

  5. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  6. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  7. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  8. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  9. In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?...

  10. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  11. Managed access

    Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  12. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

  13. Topiramate to prevent recurrent cluster headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache?

    headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache? Any explanatory notes(if...

  14. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

  15. What is the clinical effectiveness of clozapine for children and young people with schizophrenia with symptoms unresponsive to antipsychotic medication and psychological treatment combined?

    with symptoms unresponsive to antipsychotic medication and psychological treatment combined? Any explanatory notes(if applicable) The...

  16. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  17. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

  18. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

  19. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  20. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  21. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

  22. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  23. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  24. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  25. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

  26. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  27. Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)

    NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA978

  28. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

  29. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

  30. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  31. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

  32. What is the clinical effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers?

    is the clinical effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers? Any explanatory notes(if...

  33. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

  34. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  35. Eliglustat for treating type 1 Gaucher disease (HST5)

    Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.

  36. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  37. Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) (TA859)

    After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.

    Sections for TA859

  38. What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?

    Question What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?...

  39. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    Recommendation ID NG80/9 Question Decreasing pharmacological treatment:- In adults, young people and children with well-controlled...

  40. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

  41. Bisphosphonates for treating osteoporosis. Patient decision aid on bisphosphonates for treating osteoporosis

    want to think about having bisphosphonate treatment. You can choose whether to have bisphosphonate treatment or not. There...

  42. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.

  43. Nusinersen for treating spinal muscular atrophy (TA588)

    Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.

  44. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  45. What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic ovary syndrome?

    NG198/2 Question What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic...

  46. Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

    Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.

  47. Physical treatments for acne vulgaris and acne vulgaris-related scarring:  What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?

    Physical treatments for acne vulgaris and acne vulgaris-related scarring: What is the effectiveness of chemical peels for the...

  48. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.